---
title: "Pneumonia"
order: 2
category: "Pulmonology"
---

# Pneumonia

## Overview

Pneumonia is an acute infection of the pulmonary parenchyma caused by bacteria, viruses, fungi, or other microorganisms. It remains one of the leading causes of morbidity and mortality worldwide, particularly in the very young, elderly, and immunocompromised. Pneumonia is classified based on the setting of acquisition: community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Accurate diagnosis, severity assessment, and appropriate empiric antibiotic therapy are critical for improving outcomes.

### Epidemiology

**Global burden**:
- 450 million cases annually worldwide
- 4 million deaths per year
- Leading infectious cause of death globally
- Sixth leading cause of death in United States

**Community-acquired pneumonia (CAP)**:
- Incidence: 5-11 cases per 1,000 adults annually
- Hospitalization rate: 20-40% of cases
- Mortality: <1% outpatient, 5-15% hospitalized, 20-30% ICU

**Hospital-acquired pneumonia (HAP)**:
- Incidence: 5-10 cases per 1,000 hospital admissions
- Most common healthcare-associated infection
- Mortality: 30-50%

**Ventilator-associated pneumonia (VAP)**:
- Incidence: 10-25% of mechanically ventilated patients
- Develops 9-27% per 1,000 ventilator days
- Mortality: 20-50%

### Risk Factors

**Host factors**:
- Age: <2 years, >65 years
- Chronic lung disease (COPD, asthma, bronchiectasis, ILD)
- Cardiovascular disease
- Chronic kidney disease, liver disease
- Diabetes mellitus
- Immunosuppression (HIV, transplant, chemotherapy, corticosteroids)
- Aspiration risk (dysphagia, altered mental status, GERD)
- Malnutrition, alcoholism
- Smoking

**Environmental factors**:
- Crowding (nursing homes, shelters, prisons)
- Air pollution
- Occupational exposures

## Community-Acquired Pneumonia (CAP)

### Microbiology

**Most common pathogens**:
- **Streptococcus pneumoniae**: Most common (20-30%)
- **Haemophilus influenzae**: 10-20%
- **Mycoplasma pneumoniae**: 10-20% (more common in young adults)
- **Chlamydophila pneumoniae**: 5-10%
- **Respiratory viruses**: Influenza, RSV, rhinovirus, coronavirus (15-25%)
- **Legionella pneumophila**: 2-8% (outbreaks, travel-associated)
- **Staphylococcus aureus**: Post-influenza, IVDU (5%)
- **Moraxella catarrhalis**: COPD patients
- **Gram-negative bacilli**: Aspiration, structural lung disease (rare)

**Atypical pathogens** (no cell wall, intracellular):
- Mycoplasma pneumoniae
- Chlamydophila pneumoniae
- Legionella pneumophila

**Less common pathogens**:
- Anaerobes (aspiration pneumonia)
- Mycobacterium tuberculosis (endemic areas, immunocompromised)
- Endemic fungi (Histoplasma, Coccidioides, Blastomyces)
- Pneumocystis jirovecii (HIV, CD4 <200)

**Risk factors for specific pathogens**:
- **Pseudomonas aeruginosa**: Structural lung disease (bronchiectasis, cystic fibrosis), recent hospitalization, recent antibiotics, corticosteroids
- **MRSA**: Recent influenza, IVDU, recent hospitalization, known MRSA colonization
- **Legionella**: Recent travel, hot tubs, water exposure, immunosuppression
- **Aspiration organisms** (anaerobes, gram-negatives): Altered mental status, dysphagia, witnessed aspiration

### Pathophysiology

**Route of infection**:
- **Microaspiration**: Most common (oropharyngeal secretions during sleep)
- Inhalation of respiratory droplets
- Hematogenous spread (rare)

**Pulmonary defense mechanisms**:
- Upper airway: Cough, mucociliary clearance
- Lower airway: Alveolar macrophages, neutrophils, complement, antibodies
- Impairment leads to pneumonia (aspiration, immunosuppression, viral infection)

**Pathologic stages** (classic lobar pneumonia):
1. **Congestion** (24 hours): Vascular engorgement, edema, bacteria proliferation
2. **Red hepatization** (2-3 days): RBCs, neutrophils in alveoli, firm consistency
3. **Gray hepatization** (4-6 days): Fibrin, disintegrating cells, diminished vascularity
4. **Resolution** (7-11 days): Enzymatic digestion of exudate, restoration of normal architecture

**Patterns**:
- **Lobar pneumonia**: Consolidation of entire lobe (S. pneumoniae)
- **Bronchopneumonia**: Patchy infiltrates (S. aureus, H. influenzae)
- **Interstitial pneumonia**: Alveolar wall inflammation (atypicals, viruses)

### Clinical Presentation

**Typical (bacterial) pneumonia**:
- **Abrupt onset** (hours to 1-2 days)
- **Fever**: High-grade (>38.5°C), rigors
- **Cough**: Productive, purulent sputum (rust-colored in S. pneumoniae)
- **Pleuritic chest pain**: Sharp, worsens with breathing
- **Dyspnea**: Severity depends on extent of infection
- **Constitutional symptoms**: Malaise, fatigue, myalgias, headache

**Atypical pneumonia**:
- **Gradual onset** (days to weeks)
- **Fever**: Low-grade to moderate
- **Cough**: Nonproductive, persistent
- **Extrapulmonary symptoms**: More prominent (headache, myalgias, GI symptoms)
- **Minimal chest pain**

**Legionella pneumonia** (distinctive features):
- High fever, relative bradycardia
- GI symptoms (diarrhea, nausea, vomiting)
- Neurologic symptoms (confusion, headache)
- Hyponatremia, elevated transaminases

**Elderly presentation**:
- Often atypical (minimal or absent fever)
- Altered mental status, delirium
- Falls, functional decline
- Tachypnea may be only sign

**Physical examination**:
- **Vital signs**: Fever, tachypnea (>20 breaths/min), tachycardia, hypoxemia
- **Inspection**: Use of accessory muscles, cyanosis (severe)
- **Palpation**: Increased tactile fremitus over consolidation
- **Percussion**: Dull over consolidation
- **Auscultation**:
  - **Crackles** (rales): Fine, localized (most common finding)
  - **Bronchial breath sounds**: Over consolidation
  - **Egophony**: "E" to "A" change (consolidation)
  - **Decreased breath sounds**: Effusion
  - **Wheezing**: Bronchospasm (viral, mycoplasma)

### Diagnosis

**Clinical diagnosis**:
- Acute respiratory symptoms (cough, dyspnea, sputum)
- Fever (>38°C) or hypothermia (<36°C)
- Abnormal lung examination (crackles, bronchial sounds, dullness)
- New infiltrate on chest imaging

**Chest X-ray**:
- **Recommended for all patients** with suspected pneumonia
- Confirms diagnosis, assesses extent, identifies complications
- **Patterns**:
  - Lobar consolidation (air bronchograms)
  - Patchy infiltrates (bronchopneumonia)
  - Interstitial infiltrates (atypical, viral)
  - Cavitation (S. aureus, anaerobes, TB, fungi)
  - Pleural effusion (10-40% of CAP)
- **Limitations**: Early infection may not show infiltrate, dehydration may mask infiltrate

**Laboratory tests**:

*All hospitalized patients*:
- **Complete blood count**: Leukocytosis (>12,000) or leukopenia (<4,000), left shift
- **Basic metabolic panel**: Assess renal function, electrolytes, hydration
- **Arterial blood gas or pulse oximetry**: Hypoxemia
- **Blood cultures × 2**: Before antibiotics (positive in 10-20%)
- **Sputum Gram stain and culture**: If good-quality sample (>25 PMNs, <10 epithelial cells per low-power field)

*Selected patients*:
- **Legionella urinary antigen**: If severe pneumonia, travel history, outbreak, failure of β-lactam therapy
  - Detects Legionella pneumophila serogroup 1 (most common)
- **Pneumococcal urinary antigen**: Severe pneumonia, pleural effusion, immunocompromised
  - Sensitivity 70-80%, specificity >90%
- **Respiratory viral panel (PCR)**: Influenza season, outbreak, immunocompromised
- **Procalcitonin**: Distinguishes bacterial from viral (>0.25 ng/mL suggests bacterial)
- **HIV test**: All patients 18-64 years (if status unknown)

*Special circumstances*:
- **Acid-fast bacilli (AFB) sputum smear and culture**: TB risk factors
- **Fungal cultures**: Endemic areas, immunocompromised
- **Bronchoscopy with bronchoalveolar lavage (BAL)**: Immunocompromised with non-resolving pneumonia, suspected unusual pathogens

**Chest CT**:
- Not routinely indicated
- Useful if chest X-ray negative but high clinical suspicion
- Evaluate for complications (abscess, empyema)
- Differentiate from other processes (malignancy, pulmonary embolism)

### Severity Assessment

**CURB-65 score** (predicts mortality, guides site of care):
- **C**: Confusion (new onset, disorientation)
- **U**: Urea (BUN >19 mg/dL or 7 mmol/L)
- **R**: Respiratory rate ≥30 breaths/min
- **B**: Blood pressure (SBP <90 mmHg or DBP ≤60 mmHg)
- **65**: Age ≥65 years

**Scoring**:
- 0-1 points: Low risk, outpatient treatment (mortality <3%)
- 2 points: Intermediate risk, consider hospital admission (mortality 9%)
- ≥3 points: High risk, hospitalize (severe: ≥4, consider ICU) (mortality 15-40%)

**Pneumonia Severity Index (PSI)** or **PORT score**:
- More complex, 20 variables
- Stratifies into risk classes I-V
- Class I-II: Outpatient (mortality <1%)
- Class III: Brief hospitalization or outpatient with close follow-up (mortality 3%)
- Class IV-V: Hospitalize (mortality 9-30%)

**Criteria for ICU admission** (severe CAP):
- Major criteria (≥1):
  - Septic shock requiring vasopressors
  - Respiratory failure requiring mechanical ventilation
- Minor criteria (≥3 of following):
  - Respiratory rate ≥30/min
  - PaO₂/FiO₂ <250
  - Multilobar infiltrates
  - Confusion/disorientation
  - BUN ≥20 mg/dL
  - Leukopenia (WBC <4,000)
  - Thrombocytopenia (platelets <100,000)
  - Hypothermia (<36°C)
  - Hypotension requiring aggressive fluid resuscitation

### Treatment

**Principles**:
- Initiate antibiotics **within 4-8 hours** of presentation (sooner if severe)
- Empiric therapy based on:
  - Setting (outpatient, inpatient non-ICU, ICU)
  - Risk factors for resistant organisms (MRSA, Pseudomonas)
  - Local resistance patterns
- Obtain cultures before antibiotics (do not delay treatment)

**Empiric antibiotic therapy** (IDSA/ATS 2019 guidelines):

*Outpatient*:

**Otherwise healthy, no recent antibiotic use**:
- **Amoxicillin** 1 g PO TID OR
- **Doxycycline** 100 mg PO BID OR
- **Macrolide** (if local pneumococcal resistance <25%):
  - Azithromycin 500 mg day 1, then 250 mg daily × 4 days
  - Clarithromycin 500 mg BID × 7 days

**Comorbidities** (COPD, diabetes, heart/liver/renal disease, alcoholism, malignancy, asplenia):
- **Amoxicillin-clavulanate** 500/125 mg or 875/125 mg PO TID PLUS **macrolide** OR
- **Amoxicillin-clavulanate PLUS doxycycline** OR
- **Respiratory fluoroquinolone alone**:
  - Levofloxacin 750 mg daily
  - Moxifloxacin 400 mg daily

*Hospitalized (non-ICU)*:
- **β-lactam PLUS macrolide**:
  - Ceftriaxone 1-2 g IV daily OR cefotaxime 1-2 g IV every 8 hours OR ampicillin-sulbactam 1.5-3 g IV every 6 hours
  - PLUS azithromycin 500 mg IV/PO daily
- **Respiratory fluoroquinolone alone**:
  - Levofloxacin 750 mg IV/PO daily OR moxifloxacin 400 mg IV/PO daily

*Hospitalized (ICU)*:
- **β-lactam PLUS macrolide or fluoroquinolone**:
  - Ceftriaxone 2 g IV daily OR cefotaxime 2 g IV every 8 hours OR ampicillin-sulbactam 3 g IV every 6 hours
  - PLUS azithromycin 500 mg IV daily OR levofloxacin 750 mg IV daily

*Risk factors for MRSA* (recent hospitalization, recent IV antibiotics, known colonization):
- **Add vancomycin** 15 mg/kg IV every 12 hours (target trough 15-20 μg/mL) OR
- **Linezolid** 600 mg IV/PO every 12 hours

*Risk factors for Pseudomonas* (structural lung disease, recent hospitalization, recent antibiotics):
- **Anti-pseudomonal β-lactam**:
  - Piperacillin-tazobactam 4.5 g IV every 6 hours
  - Cefepime 2 g IV every 8 hours
  - Meropenem 1 g IV every 8 hours
- **PLUS ciprofloxacin or levofloxacin** (if β-lactam + fluoroquinolone) OR
- **PLUS aminoglycoside PLUS macrolide or fluoroquinolone** (if β-lactam + macrolide)

**Duration**:
- Minimum 5 days (if afebrile 48-72 hours, clinically stable, no >1 CAP-associated sign of instability)
- Typical: 5-7 days for most cases
- Longer (7-14 days): Severe pneumonia, ICU admission, complications (empyema, abscess), bacteremia, MRSA, Pseudomonas, Legionella

**De-escalation**:
- Narrow antibiotics based on culture results
- Switch from IV to oral when clinically improving, tolerating PO, afebrile 48 hours, hemodynamically stable

**Adjunctive therapy**:
- **Oxygen**: Target SpO₂ ≥90% (or PaO₂ ≥60 mmHg)
- **Fluid resuscitation**: If sepsis or hypotension
- **Vasopressors**: If fluid-refractory shock
- **Corticosteroids**: Controversial
  - Consider in severe CAP with refractory septic shock
  - Methylprednisolone 0.5 mg/kg every 12 hours × 5 days
  - May reduce need for mechanical ventilation, mortality (some studies)
- **Mechanical ventilation**: If respiratory failure

**Criteria for clinical stability** (all required):
- Temperature ≤37.8°C (100°F)
- Heart rate ≤100 bpm
- Respiratory rate ≤24/min
- Systolic BP ≥90 mmHg
- Oxygen saturation ≥90% or PaO₂ ≥60 mmHg on room air
- Able to eat
- Normal mental status

**Follow-up chest X-ray**:
- Not routinely needed if clinical improvement
- Recommended at 6-12 weeks in high-risk patients (age >50, smokers) to exclude underlying malignancy

## Hospital-Acquired Pneumonia (HAP)

### Definition and Classification

**Hospital-acquired pneumonia (HAP)**: Pneumonia occurring ≥48 hours after hospital admission, not incubating at admission.

**Ventilator-associated pneumonia (VAP)**: Pneumonia occurring >48-72 hours after endotracheal intubation.

**Healthcare-associated pneumonia (HCAP)**: Term no longer used in guidelines (heterogeneous group, empiric coverage similar to HAP/VAP not justified for all)

### Microbiology

**Common pathogens**:
- **Gram-negative bacilli** (60-70%):
  - Pseudomonas aeruginosa (20-30%)
  - Klebsiella pneumoniae
  - Escherichia coli
  - Enterobacter spp.
  - Acinetobacter baumannii
- **Gram-positive cocci** (30-40%):
  - Staphylococcus aureus (MRSA and MSSA) (30%)
  - Streptococcus pneumoniae (rare in HAP/VAP)

**Multidrug-resistant (MDR) organisms**:
- MRSA
- Pseudomonas aeruginosa (MDR strains)
- Extended-spectrum β-lactamase (ESBL)-producing organisms (K. pneumoniae, E. coli)
- Carbapenem-resistant Enterobacteriaceae (CRE)
- MDR Acinetobacter

**Risk factors for MDR pathogens**:
- Prior IV antibiotics within 90 days
- Septic shock at presentation
- Acute respiratory distress syndrome preceding VAP
- ≥5 days hospitalization prior to occurrence
- Acute renal replacement therapy prior to VAP onset

### Pathogenesis

**Routes of infection**:
- **Aspiration of oropharyngeal secretions**: Most common (colonization with nosocomial organisms)
- **Microaspiration around endotracheal tube cuff** (VAP)
- **Contaminated respiratory equipment**
- **Hematogenous spread**: Rare (bacteremia, IV catheters)

**Pathogenesis**:
- Colonization of oropharynx and stomach with nosocomial organisms
- Impaired host defenses (critical illness, sedation, supine position)
- Aspiration into lower respiratory tract
- Bacterial proliferation, lung inflammation

### Clinical Presentation

**Symptoms and signs**:
- New or progressive infiltrate on chest X-ray
- Plus ≥2 of following:
  - Fever (>38°C) or hypothermia (<36°C)
  - Leukocytosis (>12,000) or leukopenia (<4,000)
  - Purulent respiratory secretions

**VAP**:
- Fever, leukocytosis
- Worsening oxygenation (increased FiO₂ or PEEP requirements)
- Purulent tracheal secretions
- New or progressive infiltrate on chest X-ray

**Challenges in diagnosis**:
- Nonspecific clinical criteria (low specificity)
- Chest X-ray changes may be due to other causes (ARDS, atelectasis, pulmonary edema, hemorrhage)
- Fever and leukocytosis common in ICU for other reasons

### Diagnosis

**Clinical diagnosis** (less specific than CAP):
- New infiltrate on chest X-ray
- Clinical signs (fever, leukocytosis, purulent secretions)
- Exclude other causes (heart failure, ARDS, atelectasis, PE)

**Microbiologic diagnosis**:

*Sputum or tracheal aspirate*:
- Gram stain and culture
- Semi-quantitative cultures
- Low specificity (contamination with colonizing organisms)

*Quantitative cultures* (more specific):
- **Bronchoalveolar lavage (BAL)**: ≥10⁴ CFU/mL
- **Protected specimen brush (PSB)**: ≥10³ CFU/mL
- **Endotracheal aspirate**: ≥10⁵ CFU/mL
- Higher specificity than non-quantitative

*Blood cultures*:
- Positive in 10-20%
- High specificity if positive

**Biomarkers**:
- **Procalcitonin**: May help distinguish bacterial pneumonia, guide antibiotic duration

**Invasive sampling vs. non-invasive**:
- Invasive (bronchoscopy with BAL/PSB): More specific, guides de-escalation
- Non-invasive (tracheal aspirate): Easier to obtain, adequate for most cases
- No mortality difference in trials

### Treatment

**Empiric antibiotic therapy** (IDSA/ATS 2016 guidelines):

**HAP/VAP without risk factors for MDR or in units with low MRSA/Pseudomonas rates**:
- **Piperacillin-tazobactam** 4.5 g IV every 6 hours OR
- **Cefepime** 2 g IV every 8 hours OR
- **Levofloxacin** 750 mg IV daily OR
- **Meropenem** 1 g IV every 8 hours

**HAP/VAP with risk factors for MDR or in units with high MRSA/Pseudomonas rates**:

*Coverage for Pseudomonas and other gram-negative bacilli*:
- **Anti-pseudomonal β-lactam**:
  - Piperacillin-tazobactam 4.5 g IV every 6 hours (extended infusion)
  - Cefepime 2 g IV every 8 hours
  - Ceftazidime 2 g IV every 8 hours
  - Meropenem 1 g IV every 8 hours
  - Imipenem 500 mg IV every 6 hours OR 1 g every 8 hours
- **PLUS second anti-pseudomonal agent** (from different class):
  - Fluoroquinolone: Ciprofloxacin 400 mg IV every 8 hours OR levofloxacin 750 mg IV daily
  - Aminoglycoside: Gentamicin or tobramycin 7 mg/kg IV daily OR amikacin 20 mg/kg IV daily

*Coverage for MRSA*:
- **Vancomycin** 15 mg/kg IV every 12 hours (target trough 15-20 μg/mL) OR
- **Linezolid** 600 mg IV every 12 hours

**Special situations**:
- **ESBL producers**: Carbapenem (meropenem, imipenem)
- **Carbapenem-resistant Enterobacteriaceae (CRE)**: Polymyxin B or colistin, ceftazidime-avibactam, meropenem-vaborbactam
- **MDR Acinetobacter**: Carbapenem + polymyxin or colistin, sulbactam-based regimens

**De-escalation**:
- Narrow antibiotics based on culture results and antibiotic susceptibilities
- Discontinue MRSA coverage if MRSA not isolated
- Reduce to monotherapy if organism susceptible

**Duration**:
- **7 days** for most HAP/VAP (adequate if clinical response)
- **Longer (14 days)**: Slow clinical response, non-fermenting gram-negative bacilli (Pseudomonas, Acinetobacter), immunocompromised, lung abscess/empyema

**Procalcitonin-guided therapy**:
- Consider using procalcitonin to guide antibiotic duration
- Reduces antibiotic exposure without worsening outcomes

**Supportive care**:
- Oxygen, mechanical ventilation if needed
- Sepsis management (fluids, vasopressors)

### Prevention of HAP/VAP

**VAP bundle**:
- **Elevation of head of bed** to 30-45 degrees
- **Daily sedation vacation and spontaneous breathing trials** (reduce ventilator days)
- **Oral care with chlorhexidine** (reduces VAP)
- **Peptic ulcer disease prophylaxis** (H2 blockers or PPIs)
- **Deep vein thrombosis prophylaxis**
- **Early extubation** when clinically appropriate
- **Subglottic suctioning**: Continuous aspiration of subglottic secretions

**Other measures**:
- Hand hygiene
- Avoid unnecessary antibiotics (reduces resistance)
- Minimize sedation, early mobilization
- Avoid gastric overdistension (elevate HOB, manage NG tube feeds)

## Aspiration Pneumonia

### Overview

**Aspiration pneumonia**: Pneumonia resulting from aspiration of oropharyngeal or gastric contents into the lower respiratory tract.

**Aspiration pneumonitis** (chemical pneumonitis, Mendelson syndrome): Acute lung injury from aspiration of sterile gastric contents (acid). Not infectious, no antibiotics needed initially.

### Risk Factors

- Altered mental status (stroke, seizures, sedation, intoxication)
- Dysphagia (stroke, neuromuscular disease, esophageal disorders)
- Gastroesophageal reflux disease (GERD)
- Vomiting
- Enteral feeding (nasogastric tube)
- Endotracheal intubation
- Poor dental hygiene
- Elderly, nursing home residents

### Microbiology

**Community-acquired aspiration pneumonia**:
- Streptococcus pneumoniae, Haemophilus influenzae (most common)
- Anaerobes: Less common than previously thought
  - Bacteroides spp., Peptostreptococcus, Fusobacterium, Prevotella
  - More likely with periodontal disease, putrid sputum, necrotizing pneumonia, lung abscess

**Hospital-acquired aspiration pneumonia**:
- Gram-negative bacilli (Pseudomonas, Enterobacter, Klebsiella)
- Staphylococcus aureus (including MRSA)

### Clinical Presentation

**Aspiration pneumonitis** (chemical):
- Sudden onset (within hours)
- Dyspnea, tachypnea, hypoxemia
- Fever (non-infectious inflammation)
- Bilateral infiltrates (often lower lobes, right > left due to anatomy)
- Usually improves in 2-5 days without antibiotics

**Aspiration pneumonia** (infectious):
- Gradual onset (days)
- Fever, cough, purulent sputum
- Chest X-ray: Infiltrate in dependent lung segments (posterior upper lobes or superior lower lobes if supine; basal segments if upright)
- Putrid sputum suggests anaerobes

**Complications**:
- Lung abscess (anaerobes, S. aureus)
- Empyema
- ARDS

### Treatment

**Aspiration pneumonitis** (chemical):
- Supportive care (oxygen, mechanical ventilation if needed)
- **Do not routinely give antibiotics** (not infectious)
- If no improvement after 48 hours or clinical deterioration, consider antibiotics (secondary bacterial infection)

**Aspiration pneumonia**:

*Community-acquired*:
- **If no anaerobic risk factors**: Treat as CAP (amoxicillin-clavulanate or ceftriaxone + azithromycin)
- **If anaerobic risk factors** (periodontal disease, putrid sputum, lung abscess):
  - Ampicillin-sulbactam 1.5-3 g IV every 6 hours OR
  - Piperacillin-tazobactam 3.375-4.5 g IV every 6 hours
  - Alternatives: Clindamycin 600 mg IV every 8 hours (less preferred due to C. difficile risk) OR moxifloxacin 400 mg IV daily OR carbapenem

*Hospital-acquired*:
- Treat as HAP/VAP (broad-spectrum coverage including Pseudomonas, MRSA if risk factors)
- Piperacillin-tazobactam or carbapenem provides anaerobic coverage

**Duration**: 7-14 days (longer if lung abscess)

**Prevention**:
- Swallowing evaluation, speech therapy
- Thickened liquids, modified diet
- Elevate head of bed during and after meals
- Oral care
- Minimize sedation

## Complications

### Parapneumonic Effusion and Empyema

**Parapneumonic effusion**: Pleural effusion associated with pneumonia (40% of hospitalized CAP).

**Categories**:
- **Uncomplicated**: Small, free-flowing, pH >7.20, glucose >60, negative culture
- **Complicated**: Loculated, pH <7.20, glucose <60, positive Gram stain or culture
- **Empyema**: Frank pus in pleural space

**Management**:
- **Uncomplicated**: Antibiotics alone (usually resolves)
- **Complicated/empyema**: Antibiotics PLUS drainage
  - Chest tube insertion (large-bore or small-bore)
  - Intrapleural fibrinolytics (alteplase + DNase) if loculated
  - Video-assisted thoracoscopic surgery (VATS) if drainage inadequate

### Lung Abscess

**Definition**: Necrosis of lung parenchyma with cavity formation (>2 cm).

**Etiology**:
- Anaerobes (aspiration)
- Staphylococcus aureus (post-influenza, hematogenous)
- Klebsiella pneumoniae (alcoholics, diabetics)
- Mycobacterium tuberculosis
- Fungi (immunocompromised)

**Clinical presentation**:
- Subacute fever, cough, putrid sputum (foul-smelling)
- Weight loss, night sweats
- Chest X-ray/CT: Thick-walled cavity with air-fluid level

**Treatment**:
- Prolonged antibiotics (4-6 weeks, until cavity resolved or small residual scar)
- Clindamycin 600 mg IV every 8 hours OR ampicillin-sulbactam OR piperacillin-tazobactam
- Percutaneous or bronchoscopic drainage if no response
- Surgery (lobectomy) if refractory, massive hemoptysis, malignancy

### Septic Shock

- Sepsis-induced hypotension despite adequate fluid resuscitation
- Early recognition and treatment critical
- Early antibiotics, source control, fluid resuscitation, vasopressors (norepinephrine)

### Acute Respiratory Distress Syndrome (ARDS)

- Severe pneumonia can lead to ARDS
- Bilateral infiltrates, PaO₂/FiO₂ <300
- Lung-protective ventilation (low tidal volumes 6 mL/kg IBW, plateau pressure <30 cm H₂O)

## Prognosis

### Community-Acquired Pneumonia

**Overall mortality**: 5-15% (hospitalized), <1% (outpatient)

**Prognostic scores**:
- CURB-65, PSI (described earlier)
- Higher scores predict higher mortality

**Predictors of poor outcomes**:
- Advanced age
- Comorbidities (COPD, CHF, renal disease, liver disease, malignancy)
- Multilobar pneumonia
- Bacteremia
- Specific organisms (S. aureus, Pseudomonas, Legionella)
- Septic shock, respiratory failure
- Delayed antibiotic therapy

**Time to clinical stability**:
- Median: 3 days
- Factors associated with delayed stability: Multilobar disease, bacteremia, COPD, age >65

### Hospital-Acquired and Ventilator-Associated Pneumonia

**Mortality**: 20-50% (attributable mortality 10-15%)

**Prognostic factors**:
- Severity of underlying illness
- Multidrug-resistant organisms
- Inappropriate initial antibiotic therapy (doubles mortality)
- Septic shock
- Need for mechanical ventilation

## Key Points

- Pneumonia is a leading cause of infectious death globally; prompt diagnosis and early antibiotic therapy (within 4-8 hours) reduce mortality
- CURB-65 score predicts mortality and guides site of care in CAP: 0-1 points (outpatient), 2 points (consider admission), ≥3 points (hospitalize)
- Empiric antibiotic therapy for CAP should cover Streptococcus pneumoniae and atypical pathogens (Mycoplasma, Chlamydophila, Legionella); outpatient treatment options include amoxicillin, doxycycline, or macrolide (if local resistance <25%)
- Hospitalized CAP patients should receive combination therapy: β-lactam (ceftriaxone) plus macrolide (azithromycin) or respiratory fluoroquinolone monotherapy (levofloxacin, moxifloxacin)
- Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are often caused by multidrug-resistant organisms (Pseudomonas, MRSA); empiric therapy should include anti-pseudomonal β-lactam ± anti-MRSA agent based on risk factors
- Appropriate antibiotic duration for uncomplicated CAP is 5-7 days; HAP/VAP requires 7 days (14 days if non-fermenting gram-negatives or slow clinical response)
- Parapneumonic effusion complicates 40% of hospitalized pneumonia cases; complicated effusions (pH <7.20, glucose <60) and empyema require drainage in addition to antibiotics
- Aspiration pneumonitis (chemical injury from gastric acid) is treated supportively without antibiotics, while aspiration pneumonia (infectious) requires antibiotics covering typical CAP pathogens ± anaerobes if risk factors present

## References

1. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67.

2. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111.

3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72.

4. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax. 2003;58(5):377-382.

5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250.

6. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372(14):1312-1323.

7. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129(5):1210-1218.

8. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-526.

9. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344(9):665-671.

10. DiBardino DM, Wunderink RG. Aspiration pneumonia: A review of modern trends. J Crit Care. 2015;30(1):40-48.
